Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of a Second Generation Clusterin Antisense Oligonucleotide (OGX-011) in Combination With Docetaxel

NCT00471432 is registered in ClinicalTrials.gov with NCIC Clinical Trials Group as lead sponsor.

NCT NCT00471432
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00471432 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of a Second Generation Clusterin Antisense Oligonucleotide (OGX-011) in Combination With Docetaxel
Lead sponsor
NCIC Clinical Trials Group
Phase
Phase 1
Overall status
Completed
Start date
April 4, 2003
Completion date
December 21, 2009
Enrollment
40 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, breast cancer, kidney cancer, lung cancer, ovarian cancer, prostate cancer, unspecified adult solid tumor, protocol specific